The "Fast Money" traders share their first moves for the market open.
The "Fast Money" traders share their final trades of the day including Bank of America, Gilead and more.
CNBC's Meg Tirrell reports the latest on Gilead. Geoff Porges, Leerink Partners managing director and senior biotech analyst, weighs in.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 2 stocks with analyst recommendations, including Gilead Sciences and Autozone.
CNBC's Jim Cramer explains why he is watching pharmaceutical names.
The "Fast Money" traders share their final trades of the day including Gilead, Twitter and more.
CNBC's Meg Tirrell reports on what can be the next big biotech takeover. The "Fast Money" traders weigh in.
Biotech stocks were among the top performers in the U.S. stock market Tuesday amid a flurry of merger and product news.
Tobira Therapeutics shares surge after Allergan agrees to buy the drug developer for $1.7. CNBC's Meg Tirrell reports the details, as well as other biotech takeover targets surrounding progressive liver disease "NASH."
CNBC's Meg Tirrell reports the latest of Gilead, including the company's $5 billion debt offering and Jefferies analysts saying a deal may be imminent.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 4 stocks with analyst recommendations, including Gilead and Freeport-McMoRan.
David Katz, Matrix Asset Advisors, shares his top stock picks and weighs in on which sectors to watch.
Aside from the financial crisis, health care hasn't lagged the broader market this badly since Bill Clinton was president.
Gilead Sciences rose Tuesday after it was upgraded, citing confidence in the prospects for Gilead's HIV treatments among other factors.
The "Fast Money Halftime Report" traders and Stephanie Link, TIAA Global Asset Management, take their positions on four stocks making news today, including Goodyear Tire, Mondelez and more.
CNBC's Jim Cramer explains why he is watching Gilead Sciences and Texas Instruments.
Some of the names on the move ahead of the open.
With biotechs in the political crosshairs, is now the time to look at the space? With Michael Yee, RBC Capital biotech analyst.
Among their favorites is Tesla, which has a $200 plus market price, according to a TD Ameritrade study.
Jim Cramer noted a change in leadership for stocks on Monday, and spelled out to investors how big money will play a rate hike.